{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:56:35Z","timestamp":1768251395955,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Annals of Otorhinolaryngology, Head and Neck Diseases"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.anorl.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T12:50:42Z","timestamp":1525438242000},"page":"231-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants"],"prefix":"10.1016","volume":"135","author":[{"given":"V.","family":"L\u2019Huillier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Badet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anorl.2018.04.006_bib0115","unstructured":"Agence nationale de s\u00e9curit\u00e9 des m\u00e9dicaments et produits de sant\u00e9 (ANSM). Les anticoagulants en France\u00a0: \u00e9tats des lieux en 2014\u00a0et recommandations de surveillance. [En ligne\u00a0: http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/26ed375830c56499badf0014eb3bb81b.pdf]."},{"key":"10.1016\/j.anorl.2018.04.006_bib0120","series-title":"Fiche de bon usage du m\u00e9dicament. Fibrillation auriculaire non valvulaire. Quelle place pour les anticoagulants oraux\u00a0?","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2013"},{"key":"10.1016\/j.anorl.2018.04.006_bib0125","series-title":"Nouveaux anticoagulants oraux\u00a0: une \u00e9tude de l\u2019Assurance Maladie souligne la dynamique forte de ces nouveaux m\u00e9dicaments et la n\u00e9cessit\u00e9 d\u2019une vigilance accrue dans leur utilisation","author":"Caisse Nationale d'Assurance Maladie","year":"2013"},{"key":"10.1016\/j.anorl.2018.04.006_bib0130","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.01260213","article-title":"Dabigatran and kidney disease: a bad combination","volume":"8","author":"Knauf","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.anorl.2018.04.006_bib0135","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/15563650.2012.721888","article-title":"Hemorrhagic complications associated with dabigatran use","volume":"50","author":"Chen","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.anorl.2018.04.006_bib0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","article-title":"Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant","volume":"7","author":"Ganetsky","year":"2011","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.anorl.2018.04.006_bib0145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.anorl.2018.04.006_bib0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.anorl.2018.04.006_bib0155","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"Bansilal","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.anorl.2018.04.006_bib0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.anorl.2018.04.006_bib0165","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET-AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.anorl.2018.04.006_bib0170","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.anorl.2018.04.006_bib0175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anorl.2018.04.006_bib0180","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation clinical perspective","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.anorl.2018.04.006_bib0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.revmed.2014.08.005","article-title":"L\u2019anticoagulation dans la fibrillation atriale du sujet \u00e2g\u00e9\u00a0: point de vue du g\u00e9riatre avec un focus sur les anticoagulants oraux directs","volume":"1","author":"Vogel","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.anorl.2018.04.006_bib0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.beha.2013.07.011","article-title":"New oral anticoagulants in elderly patients","volume":"26","author":"Barco","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.anorl.2018.04.006_bib0195","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.otorri.2014.02.014","article-title":"Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant","volume":"65","author":"Garc\u00eda Callejo","year":"2014","journal-title":"Acta Otorrinolaringol Esp"},{"key":"10.1016\/j.anorl.2018.04.006_bib0200","doi-asserted-by":"crossref","first-page":"131395","DOI":"10.1155\/2013\/131395","article-title":"Coagulopathy and extremely elevated PT\/INR after dabigatran etexilate use in a patient with end-stage renal disease","volume":"2013","author":"Kim","year":"2013","journal-title":"Case Rep Med"},{"key":"10.1016\/j.anorl.2018.04.006_bib0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jmv.2014.09.002","article-title":"Proper use of apixaban: an outline for clinical practice","volume":"39","author":"Albaladejo","year":"2014","journal-title":"J Mal Vasc"},{"issue":"1","key":"10.1016\/j.anorl.2018.04.006_bib0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MBC.0b013e3280110762","article-title":"Research for bleeding tendency in patients presenting with significant epistaxis","volume":"18","author":"Dizdar","year":"2007","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.anorl.2018.04.006_bib0215","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/lary.20695","article-title":"Is severe epistaxis associated with acetylsalicylic acid intake?","volume":"120","author":"Soyka","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anorl.2018.04.006_bib0220","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00405-013-2450-z","article-title":"Is epistaxis associated with arterial hypertension? A systematic review of the literature","volume":"271","author":"Kikidis","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["European Annals of Otorhinolaryngology, Head and Neck Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879729618300620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879729618300620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T15:52:24Z","timestamp":1604245944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879729618300620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1879729618300620"],"URL":"https:\/\/doi.org\/10.1016\/j.anorl.2018.04.006","relation":{},"ISSN":["1879-7296"],"issn-type":[{"value":"1879-7296","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"European Annals of Otorhinolaryngology, Head and Neck Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anorl.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}